ArticleEuropean heart journal2023
Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation.
Article in European heart journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Integrated care management and comprehensive geriatric assessment using a mHealth-based approach in older multimorbid patients with atrial fibrillation: the AFFIRMO cluster-randomised trial.The Lancet regional health. Europe · 2026Article
- Observational
- Clinical Complexity in Atrial Fibrillation: A Call for a Multidimensional Framework.JACC. Advances · 2026Article
- Article
- Construction of a regression model and post-procedure care strategy for predicting atrial fibrillation recurrence risk after radiofrequency ablation using combined P-wave electrocardiographic markers and serum.Frontiers in cardiovascular medicine · 2026Article
- Machine Learning for Early Detection and Prevention of Disease Using Electronic Health Records.Methods in molecular biology (Clifton, N.J.) · 2026Review
- Application of Artificial Intelligence in the Early Detection and Management of Atrial Fibrillation: State-of-the-art Review.European cardiology · 2026Review
- Temporal trends in associations between social drivers and life-years lost in newly diagnosed atrial fibrillation in Denmark, 2000-22: a nationwide cohort study.The Lancet. Public health · 2026Article
- Discovery ofDiagnostics (Basel, Switzerland) · 2025Article
- Cardiac magnetic resonance imaging-derived atrial fibrosis in patients with pre-atrial fibrillation.Open heart · 2025Article
- Cardio-kidney-metabolic complexity in patients with atrial fibrillation: an analysis from the prospective GLORIA-AF registry phase III.Cardiovascular diabetology · 2025Observational
- Article
- Multimorbidity and atrial fibrillation: Envisioning integrated approaches to complex health needs.International journal of cardiology. Heart & vasculature · 2025Article
- Long-term clinical outcomes of oral anticoagulation in the older patients with atrial fibrillation aged ≥80 years: a report from the GLORIA-AF registry phase III.Age and ageing · 2025Article
- Association between cardiometabolic comorbidity and mortality in patients with atrial fibrillation.BMC cardiovascular disorders · 2025Observational
- Clinical outcomes of patients with atrial fibrillation in relation to multimorbidity status changes over time and the impact of ABC pathway compliance: a nationwide cohort study.Journal of thrombosis and thrombolysis · 2025Article
- Identification and Functional Investigation ofDiagnostics (Basel, Switzerland) · 2024Article
- Anticoagulation in patients with atrial fibrillation and chronic kidney disease: clinical complexity beyond thromboembolism.Internal and emergency medicine · 2024Article
- Article
- Global burden of atrial fibrillation/atrial flutter and its attributable risk factors from 1990 to 2021.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsReports of outcomes after atrial fibrillation (AF) diagnosis are conflicting. The aim of this study was to investigate mortality and hospitalization rates following AF diagnosis over time, by cause and by patient features.
methodsIndividuals aged ≥16 years with a first diagnosis of AF were identified from the UK Clinical Practice Research Datalink-GOLD dataset from 1 January 2001, to 31 December 2017. The primary outcomes were all-cause and cause-specific mortality and hospitalization at 1 year following diagnosis. Poisson regression was used to calculate rate ratios (RRs) for mortality and incidence RRs (IRRs) for hospitalization and 95% confidence intervals (CIs) comparing 2001/02 and 2016/17, adjusted for age, sex, region, socio-economic status, and 18 major comorbidities.
resultsOf 72 412 participants, mean (standard deviation) age was 75.6 (12.4) years, and 44 762 (61.8%) had ≥3 comorbidities. All-cause mortality declined (RR 2016/17 vs. 2001/02 0.72; 95% CI 0.65-0.80), with large declines for cardiovascular (RR 0.46; 95% CI 0.37-0.58) and cerebrovascular mortality (RR 0.41; 95% CI 0.29-0.60) but not for non-cardio/cerebrovascular causes of death (RR 0.91; 95% CI 0.80-1.04). In 2016/17, deaths caused from dementia (67, 8.0%), outstripped deaths from acute myocardial infarction, heart failure, and acute stroke combined (56, 6.7%, P < .001). Overall hospitalization rates increased (IRR 2016/17 vs. 2001/02 1.17; 95% CI, 1.13-1.22), especially for non-cardio/cerebrovascular causes (IRR 1.42; 95% CI 1.39-1.45). Older, more deprived, and hospital-diagnosed AF patients experienced higher event rates.
conclusionsAfter AF diagnosis, cardio/cerebrovascular mortality and hospitalization has declined, whilst hospitalization for non-cardio/cerebrovascular disease has increased.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.